New blood test could spot cancer early – 6,000+ join study
NCT ID NCT06304168
First seen Jun 27, 2026 · Last updated Aug 21, 2026 · Updated 4 times
Summary
This study tests a new blood and urine test that looks for DNA markers to detect cancer early and identify where it started. Researchers at Mayo Clinic will enroll about 6,150 people, including those with and without cancer. The goal is to see if these tests can accurately find cancer and guide next steps.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 6,150 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2019
- Expected to finish
-
May 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Cancer and control patients who will be seen or treated at Mayo clinic.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Aim 1 Tissue * Cases: * Patient has a biopsy confirmed diagnosis of target histology * Tissue samples from synchronous or metachronous primary cancers may be used as long as they are clearly of a different target organ. * Tumors from patients with an underlying genetic disorder pre-disposing to cancer may be included as long as they are stratified from those without * Controls: * Patient does not have the diagnosis of target histology * Aim 2 Blood * Cases: * Patient has a biopsy confirmed diagnosis of target histology or radiographic criteria that are unequivocal for diagnosis (example, meets radiographic criteria for hepatocellular carcinoma) * Controls: * Patient does not have a documented diagnosis of cancer within 1 year following blood collections * Aim 3 Urine * Cases: * Patient has a biopsy confirmed diagnosis of target histology or radiographic criteria that are unequivocal for diagnosis (example, meets radiographic criteria for hepatocellular carcinoma) * Controls: * Patient does not have a diagnosis of the target histology Exclusion Criteria: * Aim 1 Tissue * Cases and Controls: * Patient has had any transplants prior to tissue collection * Patient has received chemotherapy class drugs within 5 years prior to tissue collection * Cases: * Patient has had radiation to the current target lesion prior to tissue collection * Patient has multi-centric/multi-focal breast cancer with differing genetic profiles (ER/HER2/PR status differ; if multiple masses are present and not all are tested then exclude patient) * Patient has bilateral breast cancer/Ductal carcinoma in situ (DCIS) * Aim 2 Blood * Controls: * Patient has known cancer prior to current sample acquisition (not including basal cell or squamous cell skin cancers) (if patient has not been seen or if information is not available, the patient is still eligible) * Cases: * Patient has known cancer outside of the target cancer 5 years prior to blood collection (not including basal cell or squamous cell skin cancers) * Patient has received chemotherapy class drugs in the 5 years prior to blood collection * Patient has had any prior radiation therapy to the target lesion prior to blood collection * Patient has had an intervention to completely remove current target pathology * The current target pathology is a recurrence * Patient has had a biopsy to the target organ and/or lesion within 3 days before blood collection * Aim 3 Urine * Patient has known cancer outside of the target cancer 5 years prior to urine collection (not including basal cell or squamous cell skin cancers) * Patient has received chemotherapy class drugs in the 5 years prior to urine collection * Patient has had any prior radiation therapy to the target lesion prior to urine collection * Patient has had a biopsy to the target organ and/or lesion within 3 days before urine collection * The current target pathology is a recurrence * Patient has chronic indwelling urinary catheter * Patient has had a urinary tract infection within the 14 days prior to sample collection * If patient does not have a primary bladder, ureter or urethral cancer, patient has a history of bladder ureter, or urethral cancer * Cases: * Patient has had an intervention to completely remove current target pathology * The current target pathology is a recurrence
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hematopoietic and lymphatic system neoplasm are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The study's own enquiry address
This study publishes an address for enquiries. See it below .
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a vaccine stop GI cancers from returning?
- Can a phone app help childhood cancer survivors keep track of their health?
- Can the way we word cancer research invitations boost participation?
- A chill pill for Chemo's side effects? cooling therapy and a Blood-Flow drug take on nerve pain
- Wearable tech could spot Post-Surgery problems early
- Can an AI chatbot ease the aftermath of cancer?